M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot,Hendrik-Tobias Arkenau,Jeffrey R. Infante,Jason C. Chandler,Andrew Weickhardt,Jason D. Lickliter,John Sarantopoulos,Michael S. Gordon,Gabriel Mak,Annie St-Pierre,Lihua Tang,Bijoyesh Mookerjee,Stanley W. Carson,Siobhan Hayes,Kenneth F. Grossmann +14 more
TL;DR: Repeat oral supratherapeutic dabrafenib 300 mg BID dosing had no clinically relevant effect on QTc interval, with no new safety signals seen.
Journal ArticleDOI
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
TL;DR: The results suggest that trastuzumab had no clinically relevant effect on QTcF interval and the safety profile of trastizumab in combination with carboplatin and docetaxel was consistent with the known safety profiles of this combination.
Journal ArticleDOI
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
James Larkin,Michael S. Gordon,Fiona C Thistlethwaite,Paul Nathan,Brian I. Rini,Marcella Martignoni,Michael Shnaidman,Chiara Chiruzzi,Alessandra di Pietro,Toni K. Choueiri +9 more
TL;DR: This open-label, multicenter, dose-finding study evaluates the novel combination of avelumab + axitinib as 1L therapy in pts with aRCC to assess safety and tolerability.
Journal ArticleDOI
Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.
Filip Janku,Albiruni Ryan Abdul Razak,Michael S. Gordon,David G. Brooks,Daniel L. Flynn,Michael Kaufman,Jama Pitman,Bryan D. Smith,Neeta Somaiah,John de Groot,Guo Chen,Julia Jennings,Samer Salah,Deb Westwood,Eric Gerstenberger,Oliver Rosen,Suzanne George +16 more
TL;DR: A PK-guided dose escalation study of oral DCC-2618 in advanced solid tumors in GIST to achieve a proof-of-concept due to the heterogeneity of KIT resistance mutations, which emerge on treatment with approved KIT inhibitors.
Proceedings ArticleDOI
Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Aaron R. Hansen,Jeffrey R. Infante,Grant A. McArthur,Michael S. Gordon,Alexander M. Lesokhin,Ann-Lee Stayner,Todd M. Bauer,Shahneen Sandhu,Frank Tsai,Alexandra Snyder,Deepa S. Subramaniam,Jeong Kim,Eric Stefanich,Chi-Chung Li,Jane Ruppel,Maria Anderson,Houston Gilbert,Bruce McCall,Mahrukh Huseni,Ina Rhee,Michael J. Pishvaian +20 more
TL;DR: Tumor PD modulation and evidence of prolonged stable disease support the ongoing expansion phase to evaluate anti-tumor activity in select indications and Phase Ib trial in combination with atezolizumab (anti-PD-L1).